Department of Pediatric and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
Children's Cancer Center, Queen Silvia's Children's Hospital, Göteborg, Sweden.
Blood Adv. 2023 Mar 28;7(6):1045-1055. doi: 10.1182/bloodadvances.2022008251.
Hypodiploidy, defined as modal numbers (MNs) 45 or lower, has not been independently investigated in pediatric acute myeloid leukemia (AML) but is a well-described high-risk factor in pediatric acute lymphoblastic leukemia. We aimed to characterize and study the prognostic impact of hypodiploidy in pediatric AML. In this retrospective cohort study, we included children below 18 years of age with de novo AML and a hypodiploid karyotype diagnosed from 2000 to 2015 in 14 childhood AML groups from the International Berlin-Frankfurt-Münster (I-BFM) framework. Exclusion criteria comprised constitutional hypodiploidy, monosomy 7, composite karyotype, and t(8;21) with concurring sex chromosome loss. Hypodiploidy occurred in 81 patients (1.3%) with MNs, 45 (n = 66); 44 (n = 10) and 43 (n = 5). The most frequently lost chromosomes were chromosome 9 and sex chromosomes. Five-year event-free survival (EFS) and overall survival (OS) were 34% and 52%, respectively, for the hypodiploid cohort. Children with MN≤44 (n = 15) had inferior EFS (21%) and OS (33%) compared with children with MN = 45 (n = 66; EFS, 37%; OS, 56%). Adjusted hazard ratios (HRs) were 4.9 (P = .001) and 6.1 (P = .003). Monosomal karyotype or monosomy 9 had particular poor OS (43% and 15%, respectively). Allogeneic stem cell transplantation (SCT) in first complete remission (CR1) (n = 18) did not mitigate the unfavorable outcome of hypodiploidy (adjusted HR for OS was 1.5; P = .42). We identified pediatric hypodiploid AML as a rare subgroup with an inferior prognosis even in the patients treated with SCT in CR1.
低倍体性,定义为模式数(MNs)为 45 或更低,在儿科急性髓细胞白血病(AML)中尚未被独立研究,但在儿科急性淋巴细胞白血病中是一个描述明确的高危因素。我们旨在描述和研究儿科 AML 中低倍体性的预后影响。在这项回顾性队列研究中,我们纳入了 2000 年至 2015 年期间,14 个儿童 AML 组中,18 岁以下患有初发 AML 和低倍体核型的儿童。排除标准包括:组成性低倍体性、单体 7、复合核型以及伴有性染色体丢失的 t(8;21)。低倍体性发生在 81 例 MNs 为 45(n=66)、44(n=10)和 43(n=5)的患者中。最常丢失的染色体是染色体 9 和性染色体。低倍体组的 5 年无事件生存(EFS)和总生存(OS)分别为 34%和 52%。MN≤44(n=15)的患儿 EFS(21%)和 OS(33%)均低于 MN=45(n=66;EFS,37%;OS,56%)。调整后的危险比(HRs)分别为 4.9(P=0.001)和 6.1(P=0.003)。单体核型或单体 9 具有特别差的 OS(分别为 43%和 15%)。在首次完全缓解(CR1)中进行异基因造血干细胞移植(SCT)(n=18)并不能减轻低倍体性的不良预后(调整后的 OS HR 为 1.5;P=0.42)。我们发现儿科低倍体 AML 是一个罕见的亚组,即使在 CR1 中接受 SCT 的患者中,预后也较差。